- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Lung Cancer Screening Could Cost Medicare Billions
Every person covered by Medicare would shell out an additional $3 a month if the government agreed to pay to screen certain current and former smokers for lung cancer, a new study estimates.
Every person covered by Medicare would shell out an additional $3 a month if the government agreed to pay to screen certain current and former smokers for lung cancer, a new study estimates.
It would cost Medicare $2 billion a year to follow recent advice to offer these lung scans — and fuel angst about rising health costs that are borne by everyone, not just smokers, the study found.
Joshua Roth of the Fred Hutchinson Cancer Research Center in Seattle said the researchers merely were tallying the cost of screening, and were not "judging value" or saying whether Medicare should pay it. He led the study, which was released Wednesday and will be presented at an American Society of Clinical Oncology conference later this month.
Read the full story here: http://bit.ly/1lufB2x
Source; Modern Healthcare
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
